Infectious Disease
Research Areas
Products Related to Infectious Disease(1106)
- GC52171Clindamycin-d3 (hydrochloride)CAS: 1356933-72-6Purity: >99.00%
Clindamycin-d3 (هيدروكلوريد) هو الديوتيريوم المسمى Clindamycin.
- GC52191DeacetylanisomycinCAS: 27958-06-1Purity: >95.00%
Deacetylanisomycin هو منظم نمو قوي في النباتات ومشتق غير نشط من Anisomycin
- GC522117-[1-(1H)-Tetrazolylacetamido]desacetoxycephalosporanic AcidCAS: 56842-77-4Purity: >95.00%
A potential impurity in commercial preparations of cefazolin
- GC52224(±)-MMT5-14CAS: 2719679-31-7Purity: >98.00%
A derivative of remdesivir with antiviral activity
- GC52261Entecavir-d2CAS: 142217-69-4Purity: >99.00%
An internal standard for the quantification of entecavir
- GC52303Ethyl MycophenolateCAS: 32483-51-5Purity: >98.00%
A potential impurity found in commercial preparations of mycophenolate mofetil
- GC523243-(3-Hydroxyphenyl)propionic Acid sulfateCAS: 86321-32-6Purity: >95.00%
A metabolite of certain phenols and glycosides
- GC52326Biotin-PEG4-LL-37 (human) (trifluoroacetate salt)Purity: >90.00%
A biotinylated and pegylated form of LL-37
- GC52346IDR 1002 (trifluoroacetate salt)Purity: >95.00%
A synthetic cationic innate defense regulator peptide
- GC52351Citrullinated α-Enolase (R8 + R14) (1-19)-biotin Peptide
A biotinylated and citrullinated α-enolase peptide
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC52165 | Minosaminomycin | 51746-09-9 | >90.00% | |
| GC52171 | Clindamycin-d3 (hydrochloride) | 1356933-72-6 | >99.00% | |
Clindamycin-d3 (هيدروكلوريد) هو الديوتيريوم المسمى Clindamycin. | ||||
| GC52174 | Sulfadoxin-d4 | 1330266-05-1 | >99.00% | |
| GC52191 | Deacetylanisomycin | 27958-06-1 | >95.00% | |
Deacetylanisomycin هو منظم نمو قوي في النباتات ومشتق غير نشط من Anisomycin | ||||
| GC52211 | 7-[1-(1H)-Tetrazolylacetamido]desacetoxycephalosporanic Acid | 56842-77-4 | >95.00% | |
A potential impurity in commercial preparations of cefazolin | ||||
| GC52224 | (±)-MMT5-14 | 2719679-31-7 | >98.00% | |
A derivative of remdesivir with antiviral activity | ||||
| GC52230 | AA3-DLin | - | >95.00% | |
An ionizable cationic amino lipid | ||||
| GC52240 | BPH-1358 | 5352-53-4 | >95.00% | |
An inhibitor of UPPS and FPPS | ||||
| GC52253 | α-Enolase (1-19)-biotin Peptide | - | - | |
A biotinylated α-enolase peptide | ||||
| GC52261 | Entecavir-d2 | 142217-69-4 | >99.00% | |
An internal standard for the quantification of entecavir | ||||
| GC52272 | Jun9-72-2 | 2657659-42-0 | >98.00% | |
A SARS-CoV-2 PL pro inhibitor | ||||
| GC52291 | KAS 08 | 203861-20-5 | >95.00% | |
A STING activator | ||||
| GC52303 | Ethyl Mycophenolate | 32483-51-5 | >98.00% | |
A potential impurity found in commercial preparations of mycophenolate mofetil | ||||
| GC52315 | GK241 | 1899930-93-8 | >98.00% | |
An sPLA 2 (Type IIA) inhibitor | ||||
| GC52324 | 3-(3-Hydroxyphenyl)propionic Acid sulfate | 86321-32-6 | >95.00% | |
A metabolite of certain phenols and glycosides | ||||
| GC52326 | Biotin-PEG4-LL-37 (human) (trifluoroacetate salt) | - | >90.00% | |
A biotinylated and pegylated form of LL-37 | ||||
| GC52334 | ENPP1 Inhibitor 4e | - | >98.00% | |
An ENPP1 inhibitor | ||||
| GC52346 | IDR 1002 (trifluoroacetate salt) | - | >95.00% | |
A synthetic cationic innate defense regulator peptide | ||||
| GC52351 | Citrullinated α-Enolase (R8 + R14) (1-19)-biotin Peptide | - | - | |
A biotinylated and citrullinated α-enolase peptide | ||||
| GC52358 | Malachite Green (chloride) | 569-64-2 | >96.00% | |
A triphenylmethane dye | ||||
| GC52369 | Cecropin B (trifluoroacetate salt) | - | >95.00% | |
An antimicrobial peptide | ||||
| GC52378 | Cecropin A (trifluoroacetate salt) | - | >95.00% | |
An antimicrobial peptide | ||||
| GC52395 | Indolicidin (trifluoroacetate salt) | - | >98.00% | |
An antimicrobial peptide | ||||
| GC52403 | Ivermectin-d2 | - | >99.00% | |
An internal standard for the quantification of ivermectin | ||||